Analyst firms · HSBC · NVS
HSBC NVS price target and rating history
Novartis AG (NVS) · Health Care
HSBC rates Novartis AG (NVS) Hold, as of its latest action on Sep 10, 2026. It has published 4 rating actions on NVS since July 2023, including 1 upgrade and 2 downgrades.
- Current rating
- Hold
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on NVS
- 4
Every HSBC rating on NVS
- Sep 10, 2026
- Dec 4, 2024DowngradeHSBC downgrades to Reduce from Hold
- Dec 18, 2023DowngradeHSBC downgrades to Hold from Buy
- Jul 14, 2023InitiateHSBC starts coverage at Buy
How other firms rate NVS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Sell | Oct 30, 2026 | |
| HSBC | Hold | Sep 10, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Argus Research | Buy | $180 | Mar 11, 2026 |
| Citigroup | Buy | Jan 27, 2026 | |
| Barclays | Equal Weight | Jan 6, 2026 | |
| Morgan Stanley | Overweight | Dec 3, 2025 | |
| BofA Securities | Buy | Nov 25, 2025 |
Questions about HSBC and NVS
- What is HSBC's rating on NVS?
- HSBC rates NVS Hold, a neutral rating, as of Sep 10, 2026.
- When did HSBC last change its view on NVS?
- On Sep 10, 2026, HSBC upgrades to Hold from Reduce.
More NVS rating histories
All HSBC ratingsNVS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.